[Effectiveness and tolerance of atorvastatin for antiretroviral therapy-secondary dyslipemia].
OBJECTIVE
We investigated atorvastatin effectiveness and tolerance in HIV patients with hypercholesterolemia related to antiretroviral treatment.


METHODS
Prospective study that included HIV+ patients under antiretroviral treatment who displayed secondary dyslipemia and medical treatment criteria (according to NCEP-III). These patients were given 10 mg/day atorvastatin and hygienic-dietetic measures. If the therapeutic objectives were not achieved, the dose of atorvastatin was increased to 20 mg/day. Patients were followed up for 6 months.


RESULTS
32 patients were included. In 5 cases it was necessary to increase the dose from 10 mg atorvastatin to 20 mg. The therapeutic objective was obtained in 62% cases, with a good clinical tolerance. Only one adverse effect was noticed, which forced the removal of the drug.


CONCLUSIONS
In our study atorvastatin was effective for the treatment of dyslipemia in HIV patients, and it was safe and well tolerated.
Soler
Anna
A
Unitat de Malalties Infeccioses-VIH, Fundació Hospital-Asil de Granollers, Granollers, Barcelona, Spain.
Deig
Elisabet
E
Guil
Josep
J
Rodríguez-Martín
Marisa
M
Guelar
Ana
A
Pedrol
Enric
E
D000328:Adult; D000368:Aged; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D000069059:Atorvastatin; D005260:Female; D015658:HIV Infections / Q000188:drug therapy; D006538:Heptanoic Acids / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006937:Hypercholesterolemia / Q000139:chemically induced* / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011758:Pyrroles / Q000627:therapeutic use*
D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D000069059:Atorvastatin